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FrataxinMutations in the frataxin gene cause dorsal root ganglion demyelination and neurodegeneration, which
leads to Friedreich's ataxia. However the consequences of frataxin depletion have not been measured in
dorsal root ganglia or Schwann cells. We knocked down frataxin in several neural cell lines, including two
dorsal root ganglia neural lines, 2 neuronal lines, a human oligodendroglial line (HOG) and multiple
Schwann cell lines and measured cell death and proliferation. Only Schwann cells demonstrated a signiﬁcant
decrease in viability. In addition to the death of Schwann cells, frataxin decreased proliferation in Schwann,
oligodendroglia, and slightly in one neural cell line. Thus the most severe effects of frataxin deﬁciency were
on Schwann cells, which enwrap dorsal root ganglia neurons. Microarray of frataxin-deﬁcient Schwann cells
demonstrated strong activations of inﬂammatory and cell death genes including interleukin-6 and Tumor
Necrosis Factor which were conﬁrmed at the mRNA and protein levels. Frataxin knockdown in Schwann cells
also speciﬁcally induced inﬂammatory arachidonate metabolites. Anti-inﬂammatory and anti-apoptotic
drugs signiﬁcantly rescued frataxin-dependent Schwann cell toxicity. Thus, frataxin deﬁciency triggers
inﬂammatory changes and death of Schwann cells that is inhibitable by inﬂammatory and anti-apoptotic
drugs.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Friedreich's ataxia (FRDA) is a neurodegenerative and demyelinating
disorder that affects primarily the dorsal root ganglia, the posterior
column, spinocerebellar pathways and the pyramidal tracts of the spinal
cord [1–6]. The essential features of the neuropathology of FRDA is a
distal length-related axonal degeneration that affects the corticospinal
and dorsal spinocerebellar tracts and the dorsal columns, and the
degeneration extends towards the cell bodies in a “dying back”manner
and eventually leads to loss of dorsal root ganglion neurons [7].The non-
neurological aspects of the phenotype include cardiac hypertrophy and
insulin insensitivity [8,9]. FRDA is caused by the mutations in the
autosomal frataxin gene that lead to decreased frataxin protein. Data
from human studies and genetic models suggest that iron sulfur protein
defects and oxidative stress are the primary molecular consequences of
frataxin deﬁciency [10,11]. However, it is still unclear how these
biochemical consequences of frataxin deﬁciency result in the clinical
manifestations of FRDA includingneurodegeneration anddemyelination.
Previously, the consequences of frataxin depletion in embryonal P19
stem cells, some of which differentiate into diverse neural cell types have
been studied using antisense technology, and increased death and
decreased differentiation were observed [12]. However in Friedreich's
ataxia there is a speciﬁc demyelination anddegenerationmainly of dorsaliences, 1311 Haring Hall, Davis,
342.
assi).
ll rights reserved.root ganglia neurons, which are quite different from the neurons
produced by differentiation of p19. So, to study the speciﬁc consequences
of frataxin depletion in the DRG, neural and glial cellular environments,
weknockeddownfrataxin inDRGneural (ratDRG/mouseneuroblastoma
hybrid, ND7/23, and rat DRG-derived neuronal cell line, 50B11), neuronal
(rat PC12 and human neuronal cell line NT2), human oligodendroglial
(HOG) and Schwann (T265, ST88 and STS26T) cells. We observed strong
and selective inﬂammatory toxicityof frataxindeﬁciency toSchwanncells
which seemed interesting, because the axons of DRG neurons are
enwrapped by Schwann cells, and because Schwann cells have previously
been described to undergo a conversion to an inﬂammatory phenotype
[13–17]. Frataxin deﬁciency also inhibited cell proliferation in HOG cells,
Schwann cells andNT2 cells, but not in the 2 DRG lines and PC12. Thus by
this secondary criterion of proliferation, support cellsweremore sensitive
to frataxin-deﬁciency than DRG neurons.
2. Materials and methods
2.1. Cell culture
Human Schwann cell lines (T265, STS26T, ST88), human oligoden-
droglioma (HOG) cell line and the DRG cell line (ND7/23, rat DRG/
mouse neuroblastoma hybrid) were maintained in DMEM, supplemen-
tedwith 10%FBS, 1%pen/strep and2 mMglutamine. Rat PC12 cellswere
grown in RPMI 1640 medium containing 10% FBS, 1% pen/strep and
2 mM glutamine. Human NT2 cells were maintained in DMEM/F12
medium, supplemented with 10% FBS, 1% pen/strep, 2 mM glutamine,
Table 1
Sequences of primers used in quantitative RT-PCR for selected genes.
Gene
name
Species Primer
name
Primer sequences
IL1B Human IL1B-F 5′-AAA CAG ATG AAG TGC TCC TTC CAG G-3′
IL1B-R 5′-TGG AGA ACA CCA CTT GTT GCT CCA-3′
IL6 Human IL6-F 5′-CAC TCA CCT CTT CAG AAC G-3′
IL6-R 5′-ATT TGT GGT TGG GTC AGG G-3′
TNF Human TNF-F 5′-ACA AGC CTG TAG CCC ATG TT-3′
TNF-R 5′-AAA GTA GAC CTG CCC AGA CT-3′
NFkB2 Human NFkB2-F 5′-GGA GCA AGA GGC CAA AGA ACT-3′
NFkB2-R 5′-TAC AGG CCG CTC AAT CTT CAT-3′
NFkB1 Human NFkB1-F 5′-ATA GCA CTG GCA GCT TCA CAA-3′
NFkB1-R 5′-CGA AGC TGG ACA AAC ACA GAG-3′
Fxn⁎ Mouse/rat Fxn-F⁎ 5′-GAT CAA CAA GCA GAC CCC AAA-3′
Fxn-R⁎ 5′-AGG CCA ATG AAG ACA AGT CCA-3′
FXN⁎ Human FXN-F 5′-ACT AGC AGA GGA AAC GCT GG-3′
FXN-R 5′-AGG CTT TAG TGA GCT CTG CG-3′
GAPDH Human GAPDH-F 5′-CCC CTG GCC AAG GTC ATC CAT G-3′
GAPDH-R 5′-CAG TGA GCT TCC CGT TCA GCT C -3′
GAPDH Rat GAPDH-F 5′ TCA AGA AGG TGG TGA AGC AGG 3′
GAPDH-R 5′ GGT CTG GGA TGG AAT TGT GAG 3′
⁎ Fxn/FXN: Frataxin, Fxn-F⁎/Fxn-R⁎: the forward and reverse primers are located in the
consensus sequences of rat and mouse Frataxin gene.
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neuronal cell line, 50B11, was maintained in Neurobasal medium
supplemented with 10% FBS, 2% B-27 Supplement (Invitrogen), 0.1%
glucose, 0.5 mM glutamine and 5 µg/ml blasticidin (Invitrogen). Cells
were passaged every 3–4 days.
2.2. Cell cycle analysis
About 0.7 million cells were harvested and washed with PBS. The
cell pellet was resuspended in 0.5 ml PBS, and ﬁxed in 70% ethanol at
−20 °C overnight. The ethanol-suspended cells were centrifuged and
washed with PBS. The cell pellet was suspended in 0.5 ml staining
buffer (0.02 mg/ml PI, 0.1% (v/v) Triton X-100 in PBS, 0.2 mg/ml
RNase A) and incubated 15 min at 37 °C then analyzed by ﬂow
cytometry (Becton Dickinson FACScan) at the UCDavis Optical Biology
Shared Resource. Triplicate wells were used for each experiment.
2.3. Cell growth assay
Trypan Blue exclusion Assay: Reverse transfection was performed
with 0.3 million cells per well in 6-well plates. At different time points
(range from 1 to 3 days) after the transfection cells were harvested
and counted by vi-cell (Beckman coulter). For Schwann cells and HOG
cells, the ﬂoating and attached cells were harvested and counted
separately. The experiments were repeated at least 3 times using
triplicate wells for each treatment.
2.4. Apoptosis assay — Alexa Fluor 488 annexin V and PI double staining
Alexa Fluor 488-labeled annexin V and PI double staining assay was
used to examine the frataxin deﬁciency-dependent apoptosis using the
Vybrantapoptosis assaykit#2(Invitrogen). Brieﬂy, cellswereharvested
andwashed in cold PBS. The cell pellet was resuspended in 100 µl of 1×
annexin-binding buffer prior to the incubation with Annexin V/PI for
15 min at room temperature in the dark. After the incubation, 400 µl of
1× annexin-binding buffer was added and keep the samples on ice for
analysis on the ﬂow cytometer. Thirty thousand cells were analyzed per
sample. Apoptotic cells were deﬁned as FITC+/PI− cells. Triplicate
wells were used for each experiment.
2.5. Microarray
Microarray sample preparation and data analysis was performed
as previously described [18].
2.6. Oxylipin proﬁling assay
The same number of cells was plated on each culture dishes for
siRNA transfection. 3 days post-transfection, media were collected
and spinned to removed cells and debris. The supernatants were
frozen until the oxylipin proﬁling assay. The oxylipins were quantiﬁed
by HPLC/MS/MS using internal standard methods [19].
2.7. Quantitative PCR
Quantitative PCR was performed as previously described using the
Lightcycler 1.2 or Lightcycler 480 (Roche). The sequences of each
primer pair for each gene are shown in Table 1.
2.8. Cytokine assay
Cytokine protein expressions were assayed in cell culture super-
natants using Pierce's SearchLight™ multiplex sandwich ELISA
analysis service or using luminex assay service from Department of
Pathology and Laboratory Medicine's Clinical Proteomics Core at UC
Davis. Brieﬂy, cell culture medium was collected and centrifuged toremove cells or debris. The supernatants were frozen and shipped on
dry ice. The cytokine concentrations were normalized to per ml cell
culture supernatant per million cells.
2.9. siRNA transfection
Reverse transfection involving simultaneously transfecting and
plating cellswas performedusing Lipofectamine 2000 according to the
manufacture protocol (Invitrogen). Brieﬂy, transfection mix including
siRNA (30 nM ﬁnal concentration, except 40 nM for ND7/23) and
transfection reagentwasmade and added to thewells in 6-well plates.
The cells were harvested by trypsinization and about 0.3 million cells
was plated in the wells with the transfection mix. siRNAs used in the
study includes: human frataxin siRNA described previously [20], AAC
GUG GCC UCA ACC AGA UUU, and scrambled siRNA, CAG UCG CGU
UUG CGA CUG GdTdT, human frataxin siRNA (ON-TARGETplus duplex
#J-006691-07 ) and non-targeting siRNA (D-001810-0X), Rat frataxin
siRNA (ON-TARGETplus SMARTpool, L-104901-01), mouse frataxin
siRNA (ON-TARGETplus SMARTpool, #L-045500-00), and control
siRNA (Non-Targeting Pool, #D-001810-10) from Dharmacon.
2.10. Western blot analysis
Cells were lysed in lysis buffer (20 mM Tris pH7.5, 150 mM NaCl,
1% NP-40, 0.5% Sodium Deoxycholate, 1 mM EDTA, 0.1% SDS)
containing protease inhibitor cocktail and phosphatase inhibitor
cocktail from Sigma (if the lysate was used for detect phosphorylated
proteins) at 4 °C for 30 min. The supernatant was recovered by
centrifugation. Equal amount of lysates (40μg) were used for
immunoblotting. Protein concentration was assayed by the Bradford
protein assay system (Bio-Rad). Western blotting was performed as
described [20] or using the Odyssey Infrared Imaging System (Li-Cor).
Primary antibodies used to detecting phosphorylated p38, JNK, p44/
42 and total p38, JNK, p44/42 are from Cell Signaling Technology.
Primary frataxin antibody was described by Tan et al. [21].
3. Results
3.1. Frataxin knockdown is selectively toxic to Schwann cells
To evaluate the effects of frataxin deﬁciency on target cell types,
we knocked down frataxin by siRNA inmultiple neuronal and glial cell
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the siRNA transfection, and residual frataxin was 20% or less of
controls, similar to levels observed in FRDA patients (Fig. 1A). Many
ﬂoating cells were only observed in frataxin-deﬁcient Schwann cells,
consistent with a toxic effect of frataxin-deﬁciency, so the ﬂoating and
the adherent cells were collected and counted separately, and viability
and cell count were determined using the Beckman Coulter Vi-Cell
cell counter. The total cell number (ﬂoating+adherent) was
signiﬁcantly reduced at day 3 in frataxin-deﬁcient Schwann cells,
HOG cells and NT2 cells, but not in the DRG lines and PC12 cells
(Fig. 1D). These results suggested that frataxin-deﬁciency either
decreased cell proliferation and/or increased cell death of the former
3 cell lines. For the HOG cells, there was no signiﬁcant decrease in
viability, and only a small increase in ﬂoating cells (Fig. 1B and C),
indicating that the decrease in cell number is the result of decreased
cell proliferation. Similar to the HOG cells, frataxin depletion inhibited
the cell proliferation without affecting the cell viability in NT2 cells
(Fig. 1B and D). By contrast, frataxin deﬁciency in Schwann cells
caused a signiﬁcant decrease in cell viability and a ﬁve-fold increase in
ﬂoating cells (Fig. 1B and C). Furthermore, we observed a similar
frataxin-dependent decrease in cell viability and increased ﬂoatingFig. 1. The effects of frataxin depletion by siRNA on proliferation and viability at day
oligodendroglioma cell line (HOG) and Human neuronal cell line (NT2), rat neuronal cell l
mRNA levels were measured by quantitative PCR and represented as percentage of the ba
depletion leads to signiﬁcantly decreased viability uniquely in Schwann cells. C, Frataxin depl
frataxin depletion causes proliferation inhibition in Schwann cells, HOG cells and NT2 cells
deviations (n=3–8, Pb0.05*, Pb0.01**, Pb0.001***).cells in twoother Schwann cell lines (ST-88 and STS26T) (S. Fig. 1A–D).
We did not observe decreased viability nor decreased cell proliferation
in the 2 DRG lines and PC12 cells.
3.2. Inhibition of cell cycle precedes apoptotic death in frataxin-deﬁcient
Schwann cells
To further dissect the cellular toxicity caused by frataxin
deﬁciency in Schwann cells, we carried out a time course study to
investigate whether the frataxin-dependent inhibition of cell
proliferation and decreased viability could be separated in time. At
24h, frataxin protein shows very small decrease by siRNA (an
average of 28%) by densitometry analysis of 3 independent
experiments, with an greater decrease (an average of about 50%)
observed at day 2 and greater than 70% at day 3 (Fig. 2E). Consistent
with these observations, the total cell number was minimally
decreased, and no signiﬁcant changes in ﬂoating cell number or
viability were observed at day 1 (Fig. 2A–C). Thus, a defect in cell
growth is signiﬁcantly perceptible before a rise in cell death. At 48h,
cell number decreased by 300,000 with respect to controls (Fig. 2A),
with a signiﬁcant increase in ﬂoating cell number and signiﬁcant3. A, Frataxin depletion by siRNA in human Schwann cell line T265 (Sch), human
ine (PC12), rat/mouse DRG cell line (ND7/23) and rat DRG cell line (50B11). Frataxin
sal expression in each cell line transfected with the scrambled siRNA (scr). B, frataxin
etion causes about 5-fold increase in ﬂoating cells in frataxin-depleted Schwann cells. D,
, but not in PC12 and two DRG neuron lines. Error Bars represent averages±standard
Fig. 2. Inhibition of cell proliferation and IL6 cytokine induction precede death in frataxin-deﬁcient Schwann cells. The ﬂoating cells and the adherent cells in the same well were
collected separately, and counted by trypan blue exclusion assay using the Beckman Coulter Vi-Cell cell counter. Total viable cell number was divided by total cell number from both
parts to obtain the viability. Frataxin depletion results in a signiﬁcant decrease in proliferation 1 day after siRNA transfection and becomes more severe at day 2 and day 3 (A).
Frataxin depletion only causes signiﬁcantly increased ﬂoating cells (B) and signiﬁcantly decreased viability (C) at day 2, and both becomes more severe at day 3. IL6 levels are
presented as fold change over the basal levels in scrambled controls (D). E, frataxin protein levels at days 1, 2 and 3 upon siRNA transfection, shown here are representative western
blotting data out of three independent experiments and bar graph from densitometry analysis of 3 independent experiments (frataxin protein levels were normalized to beta-actin
levels). Bars represent averages±standard deviations (n=3, Pb0.05⁎, Pb0.01⁎⁎, Pb0.001⁎⁎⁎).
Table 2
Flow cytometry data of HOG and Schwann cells upon frataxin depletion at day 3.
UR (dead) LL (viable) LR (early apoptotic)
Ave Stv Ave Stv Ave Stv
HOG-scr 5.3 1.1 87.0 2.5 3.5 0.9
HOG-si 8.2 0.5 80.3 1.3 4.2 0.3
Sch-scr 5.4 0.1 88.6 0.1 5.1 0.7
Sch-siFxn 21.8 1.2 46.0 1.6 29.6 0.4
Sch-si-Q-VD 10.7 2.9 66.6 4.7 20.0 2.9
HOG-scr: scramble control in HOG cells, HOG-si: siFxn in HOG cells, Sch-scr: scramble
control in Schwann cells, Sch-si: siFxn in Schwann cells, Sch-si-Q-VD: Q-VD-OPH
treatment after frataxin depletion in Schwann cells. Numbers represent averages from 3
independent experiments.
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on total cell number, ﬂoating cell number and viability were
observed at day 3 (Fig. 2 A, B, C), when frataxin protein is down
to less than 30% of control. Thus, frataxin deﬁciency causes an early
decrease in cell proliferation followed by an increase in death in
Schwann cells. Further, ﬂow cytometry analysis with frataxin-
deﬁcient Schwann cells at day 3 demonstrated that a signiﬁcantly
increased number of apoptotic cells and necrotic cells were observed
(Table 2). By contrast, no signiﬁcant increase in apoptotic cells was
found in frataxin-deﬁcient HOG cells (Table 2). Thus, frataxin-
deﬁciency triggers apoptotic death of Schwann cells, but not
oligodendroglial cells. This suggests that it is not the myelinating
phenotype per se that sensitizes cells to frataxin deﬁciency but
something more Schwann-cell speciﬁc.
Fig. 4. Frataxin depletion causes a morphological change in T265 Schwann cells
(Magniﬁcation, 20X). A, image of the scramble control of Schwann cells at day 3. B,
image of frataxin-depleted Schwann cells at day 3.
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Schwann and oligodendroglial cells
To further characterize the frataxin-dependent inhibition of cell
proliferation, cell cycle analysis was performed by ﬂow cytometry
analysis at day 3. For both Schwann cells and HOG cells, frataxin
depletion decreased the fraction of cells in S phase by about half,
increased the fraction of cells in G2M by two-fold, and increased the
fraction of cells in G0G1 by a few percent (Fig. 3). Thus, frataxin
depletion inhibits mitosis, i.e., blocks the transition from G2 to M
phase. This block in mitosis was conﬁrmed by the observation of an
increase in cell size in frataxin-inhibited cells (Fig. 4). Furthermore
peaks of cell population with DNA content greater than 4X increase in
the frataxin-deﬁcient Schwann cells, consistent with a mitotic block
(S. Fig. 2).
3.4. Frataxin knockdown causes a phenotypic change in Schwann cells
Frataxin-deﬁcient Schwann cells underwent a major morpholog-
ical change at 2 days post-knockdown. Fig. 4A shows the typical
Schwann cell morphology, i.e. elongated spindle-shaped and bipolar
morphology. By contrast, after 2 days of frataxin knockdown,
Schwann cells became more round, with large, obvious cytoplasmic
vesicular granules. More profound morphological changes were
observed at day 3 (Fig. 4B). Two other Schwann cell lines (ST88 and
STS26T) showed similar morphological changes (S. Fig. 1E–H).
3.5. Microarray of frataxin-deﬁcient cells shows a selective activation of
genes involved in inﬂammation and death
We microarrayed the Schwann cells in an attempt to identify the
pathways activated by frataxin-deﬁciency. Cells were collected 3 days
after transfecting siFxn or scrambled siRNA. mRNA was isolated with
RNeasy kit (Qiagen). Microarray sample preparation and data analysis
were performed as described [20]. We carried out microarray on
biological duplicates (2 scr vs. 2 siFxn). The top 500 upregulated, and
top 500 down-regulated genes (S. Table 1) were analyzed by Onto-
Express program to identify the most affected biological processes
from a given gene list. Table 3 shows that inﬂammation and apoptosis
aremost signiﬁcantly-upregulated pathways in the frataxin-depletion
Schwann cells, and that cell cycle is a top-inhibited pathway. The
microarray results supported the cellular results, i.e. an observation of
increased cell death and decreased proliferation. By contrast, we didFig. 3. Frataxin deﬁciency leads to cell proliferation inhibition and cell cycle proﬁle
alteration in both Schwann and HOG cells. Quantiﬁcation of cell cycle distribution at day
3 and statistical analysis is presented in the bar graph. Bars represent averages±
standard deviations of three independent assay samples (n=3 Pb0.05⁎, Pb0.01⁎⁎,
Pb0.001⁎⁎⁎).not observe a strong induction of inﬂammatory and apoptotic genes in
frataxin-deﬁcient HOG cells (data not shown) by microarray,
indicating that the induction of inﬂammatory and apoptotic genes is
speciﬁc to Schwann cells, even though both of these cell types are
myelinating. Inﬂammatory and death genes strongly induced in the
microarray data of frataxin-deﬁcient Schwann cells include interleu-
kin 1 beta (11×), interleukin 1 alpha (9×), interleukin 6 (7×), NFkB1Table 3
The most affected biological processes in frataxin-depletion Schwann cells (⁎).
Bioprocesses Genes p-value
Upregulated
Inﬂammatory response 27 b10–12
Immune response 33 2.18E−10
Cell–cell signaling 30 2.18E−10
Chemotaxis 15 9.55E−10
Apoptosis 27 1.18E−09
Signal transduction 59 5.58E−09
Regulation of apoptosis 15 2.26E−08
Downregulated
Cell cycle 56 b10–12
Cell division 32 b10–12
Mitosis 29 b10–12
Spindle organization and biogenesis 7 b10–12
G2 phase of mitotic cell cycle 7 3.84E−11
DNA replication 33 4.47E−11
DNA replication initiation 10 8.17E−11
⁎ The top 500 upregulated and top 500 down-regulated genes were processed by the
Onto-express program, and the output biological processes were ranked by corrected
p-value and the gene number of each biological process. The table includes the
biological processes shown on the top of the list.
Fig. 6. Cytokine protein levels are induced by frataxin deﬁciency in Schwann cells by
multiplex ELISA assay. Cytokine levels are presented as fold change over the basal levels
in scrambled controls. The average basal level (pg/ml/million cells) of each cytokine:
IL6=349.55, IL1a=1.16, GCSF=4.73, IL1b=0.74, IL8=5784, TNFa=24.64,
GMCSF=92.27. Error Bars represent averages±standard deviations (n=4, Pb0.05⁎,
Pb0.01⁎⁎, Pb0.001⁎⁎⁎).
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(PLA2G4C, 3×), phospholipase A2G6 (PLA2G6, 2 X), phospholipase
A2G7 (PLA2G7, 2×), prostaglandin-endoperoxide synthase 2 (3×),
prostaglandin E synthase (2×), and several chemokine genes.
Interestingly, our previous microarray data of FRDA patients lympho-
blasts also showed a signiﬁcant induction of several inﬂammatory
genes, including caspase 1, TNF subfamily 2 (also named TNF), IL-6,
interferon-inducible p78 and TNF alpha induced p6 [20].
3.6. Inﬂammatory genes are induced by frataxin deﬁciency in Schwann
cells at the transcript and protein levels
To conﬁrm the transcriptional inductions of inﬂammatory tran-
scripts, quantitative RT-PCRwas performed on several genes: TNF, IL6,
IL1B, NFkB1 and NFkB2 in 3 Schwann cell lines and the results are
shown in Fig. 5A and S. Fig. 1I–J. The transcripts of TNF, IL6, IL1B
increased by more than 5-fold. Multiplex sandwich ELISAs were used
tomeasure the protein levels of several cytokines: TNF, IL6, CSF3, IL1A,
IL1B, GMCSF, IL8 and IFN-alpha. Fig. 6 shows that 7 cytokine protein
levels were signiﬁcantly increased, consistent with the induction at
the mRNA level by microarray. IL6 protein was observed to have a
high basal expression and be induced by about 4 fold upon frataxin
deﬁciency (Fig. 6).
To assess the time course of cytokine induction and cell death, IL6
levels were measured 1–3 days after frataxin knockdown. Fig. 2D
shows that IL6 increased by 40% 1 day post-knockdown, a time at
which there was no signiﬁcant increase in cell death. A greater
increase was observed at 2 and 3 days. The time course study suggests
that cytokine induction preceded cell death in frataxin-deﬁcient
Schwann cells.
To insure that all effects we observed in Schwann cells were truly
frataxin-dependent rather than off-target effects of the siRNA, we
repeated our experiments with another siRNA validated to have
minimal non-speciﬁc effects (Dharmacon), We observed similar
cellular effects: morphological change, decreased viability and
proliferation and induced cytokine expressions (S. Fig. 3).
3.7. Inﬂammatory arachidonate metabolites increase in
frataxin-deﬁcient Schwann Cells
Our microarray data demonstrates an upregulation of multiple
forms of PLA2, and PLA2 activity results in the hydrolysis ofFig. 5. Inﬂammatory and death transcripts are induced by frataxin deﬁciency in T265
Schwann cells by quantitative RT-PCR. Error Bars represent averages±standard
deviations (n=3 Pb0.05⁎, Pb0.01⁎⁎, Pb0.001⁎⁎⁎).membrane phospholipids and the release of arachidonic acid, which
is a precursor of eicosanoids. Thus we measured oxidized lipids that
are mediators of inﬂammation (lipid-derived eicosanoids, including
prostaglandins, thromboxanes and leukotrienes) using HPLC coupled
with mass spectrometry. Cell culture medium was collected at day 3
post-knockdown and the metabolite concentrations were measured.
Student's t tests were used to determine the statistical signiﬁcance of
the results for each analyte. We measured 40 arachidonic acid
derivatives catalyzed by cyclooxygenase (COX) (prostaglandins) and
lipoxygenases (LOX) (leukotrienes), as well as cytochrome P450
enzymes (Fig. 7A). After application of a false discovery rate
correction (q=0.05), signiﬁcant induction of 15 metabolites from
COX pathway, LOX pathway and P450 epoxygenase–sEH metabolic
pathway were observed with Pb0.02 (Fig. 7B and C). Of the three
major branches, the LOX and COX pathway metabolites were most
strongly induced.
3.8. Anti-inﬂammatory and anti-apoptotic drugs rescue Schwann cells
from death
We tested several categories of drugs to see if we could rescue cell
death in frataxin-deﬁcient Schwann cells, including iron chelators
(DFO, L1), antioxidants (NAC, BHA, BHT, NDGA, MntBAP) and anti-
apoptotic agents (Q-VD-OPH, BAF, ZVAD). In addition, several anti-
inﬂammatory agents were tested. These compounds included: 1,
cytokine neutralizing antibodies: anti-IL6, anti-IL1B and anti-TNF; 2,
NFkB inhibitor: salicylate; 3, several phospholipase 2 inhibitors:
Quinacrine, arachidonyltriﬂuoromethyl ketone, ATFK, Methyl Arachi-
donyl Fluorophosphonate MAFP, Bromoenol lactone (BEL) and
Palmitoyl triﬂuoromethyl ketone (PACOCF3); 4, several lipoxygenase
inhibitors: MK886, COX-2 inhibitor III and indomethacin; and 5, the
anti-inﬂammatories dexamethasone (DEX), SB203580 and SKF86002.
Several concentrations of each compound were tested. The rescue
compounds were added 24h after the siRNA transfection, and were
incubated with the cells for another 48h. Afterwards, the cells were
collected for cell counting assay (ﬂoating cell number, total cell
number and viability) by vi-cell (Beckman coulter) or/and double
staining with PI and annexin V followed by ﬂow cytometry analysis.
None of the drugs described above provided rescue except the anti-
Fig. 7. Inﬂammatory arachidonate metabolites increase in frataxin-deﬁcient Schwann Cells. (A), A schematic of arachidonate pathway, (B and C),15 Inﬂammatory Lipoxygenase
metabolites are increased signiﬁcantly (with P-valueb0.02) in frataxin-deﬁcient Schwann Cells (if F-test was signiﬁcant (Pb0.05, t test for two-sample unequal variance was
applied, otherwise, t test for two-sample equal variance was applied).
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asone (250 nM), SB203580 (20 μM) and SKF86002 (10 μM).
The potent anti-apoptotic drug Q-VD-OPH was found to signiﬁ-
cantly decrease the ﬂoating cells and increase the cell viability by vi-
cell analysis (data not shown). The partial rescue from the cell death
was also conﬁrmed by ﬂow cytometry analysis (Table 2). The portion
of dead cells (UR+LR, i.e., necrotic cells+apoptotic cells) was
observed to increase upon frataxin deﬁciency compared to the
control, and the Q-VD-OPH treatment decreased the portion of dead
cell from about 52% to about 25%.
Among several types of anti-inﬂammatory drugs tested, only
dexamethasone, SB203580 and SKF86002 (2 speciﬁc inhibitors of p38
MAP kinase) partially rescued the death of frataxin-deﬁcient Schwann
cells. Both dexamethasone and SB203580 signiﬁcantly decreased the
number of ﬂoating cells and increased cell viability (Fig. 8). Cytokine
protein analysis revealed that dexamethasone treatment signiﬁcantly
decreased IL6 by 3-fold, and also signiﬁcantly decreased TNF-alphalevels and IL1alpha levels (Fig. 9). SB203580 signiﬁcantly decreased
mean IL1a levels and IL6 levels, albeit not signiﬁcantly. SKF86002,
another anti-inﬂammatory inhibitor of p38 MAP kinase, showed a
similar level of rescue as SB203580 (data not shown).
We further investigated the phosphorylation of mitogen-activated
protein (MAP) kinases by western blot. The results show that mean
phosphorylated p38 MAP kinase was increased at day 3, however the
increase was not signiﬁcant. There was no increase in the phosphor-
ylation of two other stress-related MAP kinases, c-Jun N-terminal
kinases (JNKs) and p42/ p44 MAP Kinase (Erk1 and Erk2) (Fig. 10).
Although Q-VD-OPH rescued death of frataxin-deﬁcient Schwann
cells, it did not reduce TNF and IL6 protein levels (Fig. 9). This is
consistent with the time course study (Fig. 2) and the mechanistic
view that frataxin deﬁciency causes cytokine induction and then cell
death. Thus, anti-inﬂammatories inhibit cytokine production and cell
death, whereas anti-apoptotics inhibit only death but not cytokine
production.
Fig. 8. Dexamethasone and SB203580 (a speciﬁc inhibitor of p38 MAP kinase) partially
rescue cell death in frataxin-depleted Schwann cells. Dexamethasone (250 nM) and
SB203580 (20 μM) treatment signiﬁcantly decrease the ﬂoating cells in frataxin-
depletion Schwann cells (A), Dexamethasone and SB203580 treatment signiﬁcantly
increase the viability in frataxin-depletion Schwann cells (B) Error Bars represent
averages±standard deviations (n=3 for dexamethasone treatment, n=4 for
SB203580 treatment, Pb0.05⁎, Pb0.01⁎⁎, Pb0.001⁎⁎⁎).
Fig. 9. The effect of Q-VD-OPH, Dexamethasone and SB203580 treatments on the
cytokine protein expressions. Q-VD-OPH (5 μM) does not decrease TNF and IL6 protein
levels at all, Dexamethasone signiﬁcantly decrease IL6 and IL1A protein levels and
decrease TNF protein levels non-signiﬁcantly, SB203580 decreases IL1A protein levels
signiﬁcantly and decreases IL6 protein levels non-signiﬁcantly. Error Bars represent
averages±standard deviations (n=3–8, Pb0.05⁎, Pb0.01⁎⁎, Pb0.001⁎⁎⁎).
Fig. 10. Frataxin depletion results in an insigniﬁcant increase in mean phosphorylation
of p38 MAP kinase at day 3. Western results of MAP kinase (P38, JNK and P42/44) in
scrambled controls (SCR) and frataxin-depleted Schwann cells (siFxn) at 3 days post-
knockdown (A). Bar graph represents the densitometry results of the western blots (B).
Error Bars represent averages±standard deviations (n=4). The difference in
phosphorylation of p38 MAP kinase between scrambled controls (SCR) and frataxin-
depleted Schwann cells (siFxn) is not signiﬁcant.
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4.1. Frataxin deﬁciency inhibits proliferation in multiple neural cell types
The mechanisms responsible for the demyelination and degener-
ation of dorsal root ganglion neurons in Friedreich's ataxia are poorly
understood. Here we investigated the effects of frataxin deﬁciency in
several neural cell lines, including PC12, DRG neurons, NT2, HOG cells
and Schwann cells. Frataxin deﬁciency neither inhibited the growth
nor induced death of the DRG neural cell lines. However, frataxin
deﬁciency inhibited the proliferation of Schwann cells and HOG cells,
and to a lesser extent, NT2 neural cells.
4.2. The inhibition of the cell cycle depletes S phase cells and increases
G2M cells
Frataxin deﬁciency inhibited cell cycle progression in Schwann cells,
HOG cells and NT2 cells, but only caused death in Schwann cells. Non-
synchronized cell cycle analysis demonstrated that cells were mainly
blocked inmitosis, and subsequently therewere a 2-fold increase in the
fraction of cells in G2M and increased cell size was observed under
microscope. Consistent with these observations, microarray of the
frataxin-deﬁcient cells demonstrated inhibition of mitotic transcripts.4.3. Frataxin deﬁciency induces a morphological change and death
uniquely in Schwann cells
Frataxin deﬁciency only induced signiﬁcant cell death in Schwann
cells, and not the closely-related oligodendroglial HOG cells, nor DRG
neurons, PC12 or NT2 neurons, suggesting a cell-type speciﬁc basis for
this toxicity. Also, uniquely in Schwann cells frataxin deﬁciency
induced profound morphological changes that were unlike apoptosis,
and more like the induction of a phagocytic response. This transition
to an inﬂammatory/phagocytic response has been previously noted in
a large body of studies with Schwann cells [13,16,17,22–25].
4.4. Induction of inﬂammatory and apoptotic genes precedes Schwann
cell death
We observed that frataxin deﬁciency selectively and signiﬁcantly
induced inﬂammatory and cell death transcripts in Schwann cells by
microarray, and that these increases were conﬁrmed by QRTPCR and
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be partially rescued by the anti-inﬂammatory drugs SB203580 and
SKF86002 and dexamethasone, and by the anti-apoptotic drug Q-VD-
OPH. However, drugs from the antioxidant and iron-chelation classes
had no beneﬁcial effect on the frataxin-deﬁcient Schwann cells.
It is now widely accepted that inﬂammation contributes to the
pathogenesis of many neurodegenerative diseases of both inﬂamma-
tory and primarily non-inﬂammatory origin, including Alzheimer's
disease (AD)[26,27], Parkinson's disease (PD) [28], Huntington's
disease [29], Multiple sclerosis [30], Amyotrophic lateral sclerosis
[31] and Wallerian degeneration [32], and is referred to as neuroin-
ﬂammation. Neuroinﬂammation is characterized by activated neuro-
glial cells and the secretion of inﬂammatory mediators, among which,
cytokines are thought to be the key players. In the peripheral nervous
system (PNS), Schwann cells serve as partially immune-competent
cells, capable of producing a variety of proinﬂammatory cytokines
including IL1, IL6 and TNF, and other proinﬂammatorymediators such
as prostaglandin E2, thromboxane A2 and leukotriene C4[22,33–36].
Here we demonstrated a strong inﬂammatory response upon frataxin
deﬁciency in cultured human Schwann cell lines, including the
secretion of multiples cytokines and other inﬂammatory mediators,
e.g., metabolites of arachidonic acid. Transcription factors, nuclear
factor-kappa B (NFkB1 and 2), were also upregulated, whose activity
has been implicated in regulation of the innate inﬂammatory
response including AD, i.e., upregulation of NFkB increase IL-1, IL6
and TNF-α levels [37,38]. The arachidonate pathway has been shown
to play a critical role in the production of potent inﬂammogens [39]
and in neurodegenerative diseases including AD (for review, see:
[40]). Here we demonstrate increased arachidonic acid derivatives
catalyzed by COX, LOX, and P450 pathways in frataxin-deﬁcient
Schwann cells. A further study of arachidonic acid derivatives in FRDA
patients is needed. Free radical generation and lipid peroxidation have
been thought to play a signiﬁcant role in FRDA. Upregulation of
proinﬂammatory PLA2 and the subsequent release of lipid-derived
eicosanoids may be one of the factors that are responsible for free
radical generation and lipid peroxidation in FRDA.
Schwann cells are the myelinating cells of dorsal root ganglion
neurons, and are thus in intimate physical contact with them. Thuswe
speculate that inﬂammatory cytokines produced by frataxin-deﬁcient
Schwann cells may contribute to DRG neuron toxicity. In Friedreich's
ataxia patients, microscopic examinations of autopsied heart samples
have revealed evidences of myocarditis with leukocyte inﬁltrations
[41–43], suggesting that inﬂammation may play a role in the
progressive cardiomyopathy in FRDA.
Consistent with the results in Schwann cells, we had previously
demonstrated that frataxin-deﬁcient lymphoblasts from Friedreich's
patients overexpress multiple inﬂammatory transcripts including IL-6
and TNF, and that these inﬂammatory changes were rescued by
frataxin transfection [20]. In Schwann cells, IL6 showed a very high
basal expression and a signiﬁcant induction of about 4 fold at the
protein level. Therefore we assume that IL6 functions as a very
important proinﬂammatory mediator secreted by Schwann cells.
Inﬂammation can be induced by iron accumulation and oxidative
stress [44,45], both of which have been shown to be the consequences
of frataxin deﬁciency.
5. Summary and prospects
In this study we demonstrated that frataxin deﬁciency causes the
inhibition of cell proliferation in several neuroglial cells including
Schwann, HOG and NT2 cells, but not in dorsal root ganglia and PC12
neuronal cell lines. Furthermore, frataxin deﬁciency caused a
signiﬁcant increase in cell death uniquely in Schwann cells via the
activation of inﬂammatory pathways. In consistent with the “dying
back” hypothesis of FRDA, the inﬂammogens secreted by frataxin-
deﬁcient Schwann cells could be toxic to the axons of dorsal rootganglia with which they are in intimate contact in vivo, and eventually
leads to the loss of DRG neurons. It is still unclear why frataxin
deﬁciency activates the inﬂammatory pathways and leads to cell
death selectively in Schwann cells, however these observations do
provide a cellular basis for the selective demyelination and vulner-
ability of DRG neurons in FRDA. Further in vivo investigations are
needed to conﬁrm these in vitro observations.Acknowledgements
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